Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification
Sun J, Yang Q, Lu Z et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol 2012; 138(3): 429-434.
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
O'Connor OA, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29(9): 1182-1189.
(2011)J Clin Oncol, vol.29, Issue.9, pp. 1182-1189
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
Coiffier B, Pro B, Prince HM et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30(6): 631-636.
U.S. Food and Drug Administration. Highlights of Prescribing Information for BELEODAQ® (belinostat). www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf (30 October 2014, date last accessed).
Quantitative structure-activity relationship study of histone deacetylase iinhibitors
Xie AH, Liao CZ, Li ZB et al. Quantitative structure-activity relationship study of histone deacetylase iinhibitors. Curr Med Chem Anticancer Agents 2004; 4(3): 273-299.
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
Ning ZQ, Li ZB, Newman MJ et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol 2012; 69(4): 901-909.
CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells
Gong K, Xie J, Yi H et al. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J 2012; 443(3): 735-746.
Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine
Yao Y, Zhou J, Wang L et al. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One 2013; 8(8): e70522.
Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment
Pan DS, Yang QJ, Fu X et al. Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment. Med Chem Commun 2014; 5: 1789-1796.
Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells
Zhou Y, Pan DS, Shan S et al. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells. Biomed Pharmacother 2014; 68(4): 483-491.
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
Dong M, Ning ZQ, Xing PY et al. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol 2012; 69(6): 1413-1422.
Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma
Shi YK, Dong M, Hong XN et al. Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol 2013; 31(suppl): abstr 8525.
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17(4): 1244-1253.
(1999)J Clin Oncol, vol.17, Issue.4, pp. 1244-1253
Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare longterm survivors
Mak V, Hamm J, Chhanabhai M et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare longterm survivors. J Clin Oncol 2013; 31(16): 1970-1976.
(2013)J Clin Oncol, vol.31, Issue.16, pp. 1970-1976
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13(9): 673-691.
China Food and Drug Administration. Approval summary for Epidaza® (Chidamide). www.cde.org.cn/reviewDe.do?method=showFAQ&id=127 (9 February 2015, date last accessed).
